Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer Article Swipe
Ming Lei
,
Michael J. Overman
,
Jin Yao
,
Thierry André
,
Sara Lonardi
,
Heinz‐Josef Lenz
,
Massimo Aglietta
,
Fabio Gelsomino
,
Ray McDermott
,
Ka Yeung Mark Wong
,
Michael A. Morse
,
Eric Van Cutsem
,
Alain Hendlisz
,
Dana B. Cardin
,
Bart Neyns
,
Andrew Hill
,
Anuradha Krishnamurthy
,
Franklin Chen
,
Samith T. Kochuparambil
,
Robert R. Jenq
,
Sandzhar Abdullaev
,
Beilei He
,
Ruslan D. Novosiadly
,
Scott Kopetz
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1038/s41467-025-63960-8
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1038/s41467-025-63960-8
Nivolumab alone and in combination with ipilimumab demonstrated durable clinical benefit in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer in the phase 2 CheckMate 142 study. Here, we report exploratory biomarker analyses from CheckMate 142 evaluating associations between various tissue biomarkers and the efficacy of nivolumab monotherapy and nivolumab plus ipilimumab combination in these patients. Higher expression of inflammation-related gene expression signatures is associated with improved response per investigator assessment and survival benefit with nivolumab monotherapy. In contrast, higher tumor mutational burden, tumor indel burden, and degrees of microsatellite instability are associated with improved response per investigator assessment and survival benefit with nivolumab plus ipilimumab. While interpretation is limited by the exploratory nature of these analyses, they suggest that tumor antigenicity rather than baseline tumor inflammation might be important for the combinatorial efficacy. Validation of these findings in larger, randomized studies is necessary.
Related Topics
Concepts
No concepts available.
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1038/s41467-025-63960-8
- https://www.nature.com/articles/s41467-025-63960-8.pdf
- OA Status
- gold
- References
- 40
- OpenAlex ID
- https://openalex.org/W4414851035
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4414851035Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1038/s41467-025-63960-8Digital Object Identifier
- Title
-
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancerWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-10-06Full publication date if available
- Authors
-
Ming Lei, Michael J. Overman, Jin Yao, Thierry André, Sara Lonardi, Heinz‐Josef Lenz, Massimo Aglietta, Fabio Gelsomino, Ray McDermott, Ka Yeung Mark Wong, Michael A. Morse, Eric Van Cutsem, Alain Hendlisz, Dana B. Cardin, Bart Neyns, Andrew Hill, Anuradha Krishnamurthy, Franklin Chen, Samith T. Kochuparambil, Robert R. Jenq, Sandzhar Abdullaev, Beilei He, Ruslan D. Novosiadly, Scott KopetzList of authors in order
- Landing page
-
https://doi.org/10.1038/s41467-025-63960-8Publisher landing page
- PDF URL
-
https://www.nature.com/articles/s41467-025-63960-8.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.nature.com/articles/s41467-025-63960-8.pdfDirect OA link when available
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
40Number of works referenced by this work
Full payload
| id | https://openalex.org/W4414851035 |
|---|---|
| doi | https://doi.org/10.1038/s41467-025-63960-8 |
| ids.doi | https://doi.org/10.1038/s41467-025-63960-8 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/41053075 |
| ids.openalex | https://openalex.org/W4414851035 |
| fwci | 0.0 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000627 |
| mesh[1].descriptor_ui | D000074324 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | therapeutic use |
| mesh[1].descriptor_name | Ipilimumab |
| mesh[2].qualifier_ui | Q000008 |
| mesh[2].descriptor_ui | D000074324 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | administration & dosage |
| mesh[2].descriptor_name | Ipilimumab |
| mesh[3].qualifier_ui | Q000627 |
| mesh[3].descriptor_ui | D000077594 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | therapeutic use |
| mesh[3].descriptor_name | Nivolumab |
| mesh[4].qualifier_ui | Q000008 |
| mesh[4].descriptor_ui | D000077594 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | administration & dosage |
| mesh[4].descriptor_name | Nivolumab |
| mesh[5].qualifier_ui | Q000188 |
| mesh[5].descriptor_ui | D015179 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | drug therapy |
| mesh[5].descriptor_name | Colorectal Neoplasms |
| mesh[6].qualifier_ui | Q000235 |
| mesh[6].descriptor_ui | D015179 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | genetics |
| mesh[6].descriptor_name | Colorectal Neoplasms |
| mesh[7].qualifier_ui | Q000473 |
| mesh[7].descriptor_ui | D015179 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | pathology |
| mesh[7].descriptor_name | Colorectal Neoplasms |
| mesh[8].qualifier_ui | Q000276 |
| mesh[8].descriptor_ui | D015179 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | immunology |
| mesh[8].descriptor_name | Colorectal Neoplasms |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D053842 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Microsatellite Instability |
| mesh[10].qualifier_ui | Q000627 |
| mesh[10].descriptor_ui | D000971 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | therapeutic use |
| mesh[10].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[11].qualifier_ui | Q000235 |
| mesh[11].descriptor_ui | D007249 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | genetics |
| mesh[11].descriptor_name | Inflammation |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D009154 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Mutation |
| mesh[13].qualifier_ui | Q000235 |
| mesh[13].descriptor_ui | D014408 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | genetics |
| mesh[13].descriptor_name | Biomarkers, Tumor |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D008297 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Male |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D005260 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Female |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D016896 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Treatment Outcome |
| mesh[17].qualifier_ui | Q000627 |
| mesh[17].descriptor_ui | D000074322 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | therapeutic use |
| mesh[17].descriptor_name | Antineoplastic Agents, Immunological |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D006801 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Humans |
| mesh[19].qualifier_ui | Q000627 |
| mesh[19].descriptor_ui | D000074324 |
| mesh[19].is_major_topic | True |
| mesh[19].qualifier_name | therapeutic use |
| mesh[19].descriptor_name | Ipilimumab |
| mesh[20].qualifier_ui | Q000008 |
| mesh[20].descriptor_ui | D000074324 |
| mesh[20].is_major_topic | True |
| mesh[20].qualifier_name | administration & dosage |
| mesh[20].descriptor_name | Ipilimumab |
| mesh[21].qualifier_ui | Q000627 |
| mesh[21].descriptor_ui | D000077594 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | therapeutic use |
| mesh[21].descriptor_name | Nivolumab |
| mesh[22].qualifier_ui | Q000008 |
| mesh[22].descriptor_ui | D000077594 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | administration & dosage |
| mesh[22].descriptor_name | Nivolumab |
| mesh[23].qualifier_ui | Q000188 |
| mesh[23].descriptor_ui | D015179 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | drug therapy |
| mesh[23].descriptor_name | Colorectal Neoplasms |
| mesh[24].qualifier_ui | Q000235 |
| mesh[24].descriptor_ui | D015179 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | genetics |
| mesh[24].descriptor_name | Colorectal Neoplasms |
| mesh[25].qualifier_ui | Q000473 |
| mesh[25].descriptor_ui | D015179 |
| mesh[25].is_major_topic | True |
| mesh[25].qualifier_name | pathology |
| mesh[25].descriptor_name | Colorectal Neoplasms |
| mesh[26].qualifier_ui | Q000276 |
| mesh[26].descriptor_ui | D015179 |
| mesh[26].is_major_topic | True |
| mesh[26].qualifier_name | immunology |
| mesh[26].descriptor_name | Colorectal Neoplasms |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D053842 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Microsatellite Instability |
| mesh[28].qualifier_ui | Q000627 |
| mesh[28].descriptor_ui | D000971 |
| mesh[28].is_major_topic | True |
| mesh[28].qualifier_name | therapeutic use |
| mesh[28].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[29].qualifier_ui | Q000235 |
| mesh[29].descriptor_ui | D007249 |
| mesh[29].is_major_topic | True |
| mesh[29].qualifier_name | genetics |
| mesh[29].descriptor_name | Inflammation |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D009154 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Mutation |
| mesh[31].qualifier_ui | Q000235 |
| mesh[31].descriptor_ui | D014408 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | genetics |
| mesh[31].descriptor_name | Biomarkers, Tumor |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D008297 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Male |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D005260 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Female |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D016896 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Treatment Outcome |
| mesh[35].qualifier_ui | Q000627 |
| mesh[35].descriptor_ui | D000074322 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | therapeutic use |
| mesh[35].descriptor_name | Antineoplastic Agents, Immunological |
| mesh[36].qualifier_ui | |
| mesh[36].descriptor_ui | D006801 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | |
| mesh[36].descriptor_name | Humans |
| mesh[37].qualifier_ui | Q000627 |
| mesh[37].descriptor_ui | D000074324 |
| mesh[37].is_major_topic | True |
| mesh[37].qualifier_name | therapeutic use |
| mesh[37].descriptor_name | Ipilimumab |
| mesh[38].qualifier_ui | Q000008 |
| mesh[38].descriptor_ui | D000074324 |
| mesh[38].is_major_topic | True |
| mesh[38].qualifier_name | administration & dosage |
| mesh[38].descriptor_name | Ipilimumab |
| mesh[39].qualifier_ui | Q000627 |
| mesh[39].descriptor_ui | D000077594 |
| mesh[39].is_major_topic | True |
| mesh[39].qualifier_name | therapeutic use |
| mesh[39].descriptor_name | Nivolumab |
| mesh[40].qualifier_ui | Q000008 |
| mesh[40].descriptor_ui | D000077594 |
| mesh[40].is_major_topic | True |
| mesh[40].qualifier_name | administration & dosage |
| mesh[40].descriptor_name | Nivolumab |
| mesh[41].qualifier_ui | Q000188 |
| mesh[41].descriptor_ui | D015179 |
| mesh[41].is_major_topic | True |
| mesh[41].qualifier_name | drug therapy |
| mesh[41].descriptor_name | Colorectal Neoplasms |
| mesh[42].qualifier_ui | Q000235 |
| mesh[42].descriptor_ui | D015179 |
| mesh[42].is_major_topic | True |
| mesh[42].qualifier_name | genetics |
| mesh[42].descriptor_name | Colorectal Neoplasms |
| mesh[43].qualifier_ui | Q000473 |
| mesh[43].descriptor_ui | D015179 |
| mesh[43].is_major_topic | True |
| mesh[43].qualifier_name | pathology |
| mesh[43].descriptor_name | Colorectal Neoplasms |
| mesh[44].qualifier_ui | Q000276 |
| mesh[44].descriptor_ui | D015179 |
| mesh[44].is_major_topic | True |
| mesh[44].qualifier_name | immunology |
| mesh[44].descriptor_name | Colorectal Neoplasms |
| mesh[45].qualifier_ui | |
| mesh[45].descriptor_ui | D053842 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | |
| mesh[45].descriptor_name | Microsatellite Instability |
| mesh[46].qualifier_ui | Q000627 |
| mesh[46].descriptor_ui | D000971 |
| mesh[46].is_major_topic | True |
| mesh[46].qualifier_name | therapeutic use |
| mesh[46].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[47].qualifier_ui | Q000235 |
| mesh[47].descriptor_ui | D007249 |
| mesh[47].is_major_topic | True |
| mesh[47].qualifier_name | genetics |
| mesh[47].descriptor_name | Inflammation |
| mesh[48].qualifier_ui | |
| mesh[48].descriptor_ui | D009154 |
| mesh[48].is_major_topic | False |
| mesh[48].qualifier_name | |
| mesh[48].descriptor_name | Mutation |
| mesh[49].qualifier_ui | Q000235 |
| mesh[49].descriptor_ui | D014408 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | genetics |
| mesh[49].descriptor_name | Biomarkers, Tumor |
| type | article |
| title | Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer |
| biblio.issue | 1 |
| biblio.volume | 16 |
| biblio.last_page | 8868 |
| biblio.first_page | 8868 |
| topics[0].id | https://openalex.org/T10158 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | Cancer Immunotherapy and Biomarkers |
| topics[1].id | https://openalex.org/T11067 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9994999766349792 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Colorectal Cancer Treatments and Studies |
| topics[2].id | https://openalex.org/T10335 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9973000288009644 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Colorectal Cancer Surgical Treatments |
| is_xpac | False |
| apc_list.value | 3920 |
| apc_list.currency | GBP |
| apc_list.value_usd | 4808 |
| apc_paid.value | 3920 |
| apc_paid.currency | GBP |
| apc_paid.value_usd | 4808 |
| language | en |
| locations[0].id | doi:10.1038/s41467-025-63960-8 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S64187185 |
| locations[0].source.issn | 2041-1723 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2041-1723 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Nature Communications |
| locations[0].source.host_organization | https://openalex.org/P4310319908 |
| locations[0].source.host_organization_name | Nature Portfolio |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310319908 |
| locations[0].license | cc-by-nc-nd |
| locations[0].pdf_url | https://www.nature.com/articles/s41467-025-63960-8.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Nature Communications |
| locations[0].landing_page_url | https://doi.org/10.1038/s41467-025-63960-8 |
| locations[1].id | pmid:41053075 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Nature communications |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/41053075 |
| locations[2].id | pmh:oai:doaj.org/article:727cfc372b8a42dc9e9005ca809b2540 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].source.host_organization_lineage | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Nature Communications, Vol 16, Iss 1, Pp 1-12 (2025) |
| locations[2].landing_page_url | https://doaj.org/article/727cfc372b8a42dc9e9005ca809b2540 |
| locations[3].id | pmh:oai:europepmc.org:11309114 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S4306400806 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | Europe PMC (PubMed Central) |
| locations[3].source.host_organization | https://openalex.org/I1303153112 |
| locations[3].source.host_organization_name | European Bioinformatics Institute |
| locations[3].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12501054 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5059370447 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-1292-5911 |
| authorships[0].author.display_name | Ming Lei |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210091812 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Translational Medicine, Bristol Myers Squibb, Princeton, NJ, USA |
| authorships[0].institutions[0].id | https://openalex.org/I4210091812 |
| authorships[0].institutions[0].ror | https://ror.org/00gtmwv55 |
| authorships[0].institutions[0].type | company |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210091812 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Bristol-Myers Squibb (United States) |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Ming Lei |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Translational Medicine, Bristol Myers Squibb, Princeton, NJ, USA |
| authorships[1].author.id | https://openalex.org/A5060977002 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Michael J. Overman |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I1343551460 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA |
| authorships[1].institutions[0].id | https://openalex.org/I1343551460 |
| authorships[1].institutions[0].ror | https://ror.org/04twxam07 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I1343551460 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | The University of Texas MD Anderson Cancer Center |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Michael J. Overman |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA |
| authorships[2].author.id | https://openalex.org/A5057758934 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Jin Yao |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210091812, https://openalex.org/I4210159872 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Translational Bioinformatics, Informatics & Predictive Sciences, Bristol Myers Squibb, Princeton, NJ, USA |
| authorships[2].institutions[0].id | https://openalex.org/I4210091812 |
| authorships[2].institutions[0].ror | https://ror.org/00gtmwv55 |
| authorships[2].institutions[0].type | company |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210091812 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Bristol-Myers Squibb (United States) |
| authorships[2].institutions[1].id | https://openalex.org/I4210159872 |
| authorships[2].institutions[1].ror | https://ror.org/05canvq15 |
| authorships[2].institutions[1].type | company |
| authorships[2].institutions[1].lineage | https://openalex.org/I4210159872 |
| authorships[2].institutions[1].country_code | US |
| authorships[2].institutions[1].display_name | Predictive Science (United States) |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Jin Yao |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Translational Bioinformatics, Informatics & Predictive Sciences, Bristol Myers Squibb, Princeton, NJ, USA |
| authorships[3].author.id | https://openalex.org/A5079480540 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-5103-7095 |
| authorships[3].author.display_name | Thierry André |
| authorships[3].countries | FR |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I154526488, https://openalex.org/I39804081, https://openalex.org/I4210097159, https://openalex.org/I4210102928, https://openalex.org/I4210134622 |
| authorships[3].affiliations[0].raw_affiliation_string | Sorbonne Université and Department of Medical Oncology, Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris and INSERM, Unité Mixte de Recherche Scientifique 938, and SIRIC CURAMUS, Sorbonne Université, Paris, France |
| authorships[3].institutions[0].id | https://openalex.org/I4210097159 |
| authorships[3].institutions[0].ror | https://ror.org/00pg5jh14 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210097159 |
| authorships[3].institutions[0].country_code | FR |
| authorships[3].institutions[0].display_name | Assistance Publique – Hôpitaux de Paris |
| authorships[3].institutions[1].id | https://openalex.org/I4210134622 |
| authorships[3].institutions[1].ror | https://ror.org/03wxndv36 |
| authorships[3].institutions[1].type | facility |
| authorships[3].institutions[1].lineage | https://openalex.org/I154526488, https://openalex.org/I39804081, https://openalex.org/I4210097159, https://openalex.org/I4210129850, https://openalex.org/I4210134622 |
| authorships[3].institutions[1].country_code | FR |
| authorships[3].institutions[1].display_name | Centre de Recherche Saint-Antoine |
| authorships[3].institutions[2].id | https://openalex.org/I4210102928 |
| authorships[3].institutions[2].ror | https://ror.org/01875pg84 |
| authorships[3].institutions[2].type | healthcare |
| authorships[3].institutions[2].lineage | https://openalex.org/I4210097159, https://openalex.org/I4210102928 |
| authorships[3].institutions[2].country_code | FR |
| authorships[3].institutions[2].display_name | Hôpital Saint-Antoine |
| authorships[3].institutions[3].id | https://openalex.org/I154526488 |
| authorships[3].institutions[3].ror | https://ror.org/02vjkv261 |
| authorships[3].institutions[3].type | government |
| authorships[3].institutions[3].lineage | https://openalex.org/I154526488 |
| authorships[3].institutions[3].country_code | FR |
| authorships[3].institutions[3].display_name | Inserm |
| authorships[3].institutions[4].id | https://openalex.org/I39804081 |
| authorships[3].institutions[4].ror | https://ror.org/02en5vm52 |
| authorships[3].institutions[4].type | education |
| authorships[3].institutions[4].lineage | https://openalex.org/I39804081 |
| authorships[3].institutions[4].country_code | FR |
| authorships[3].institutions[4].display_name | Sorbonne Université |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Thierry André |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Sorbonne Université and Department of Medical Oncology, Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris and INSERM, Unité Mixte de Recherche Scientifique 938, and SIRIC CURAMUS, Sorbonne Université, Paris, France |
| authorships[4].author.id | https://openalex.org/A5051613962 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-7593-8138 |
| authorships[4].author.display_name | Sara Lonardi |
| authorships[4].countries | IT |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210109345, https://openalex.org/I4210153126 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy |
| authorships[4].institutions[0].id | https://openalex.org/I4210153126 |
| authorships[4].institutions[0].ror | https://ror.org/04tfzc498 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210153126 |
| authorships[4].institutions[0].country_code | IT |
| authorships[4].institutions[0].display_name | Istituti di Ricovero e Cura a Carattere Scientifico |
| authorships[4].institutions[1].id | https://openalex.org/I4210109345 |
| authorships[4].institutions[1].ror | https://ror.org/01xcjmy57 |
| authorships[4].institutions[1].type | healthcare |
| authorships[4].institutions[1].lineage | https://openalex.org/I4210109345, https://openalex.org/I4210153126 |
| authorships[4].institutions[1].country_code | IT |
| authorships[4].institutions[1].display_name | Istituto Oncologico Veneto |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Sara Lonardi |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy |
| authorships[5].author.id | https://openalex.org/A5045441776 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-2178-9568 |
| authorships[5].author.display_name | Heinz‐Josef Lenz |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I1174212 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA |
| authorships[5].institutions[0].id | https://openalex.org/I1174212 |
| authorships[5].institutions[0].ror | https://ror.org/03taz7m60 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I1174212 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | University of Southern California |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Heinz-Josef Lenz |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA |
| authorships[6].author.id | https://openalex.org/A5056702454 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-2255-7972 |
| authorships[6].author.display_name | Massimo Aglietta |
| authorships[6].countries | IT |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210151091, https://openalex.org/I4210153126 |
| authorships[6].affiliations[0].raw_affiliation_string | Medical Oncology Department, IRCCS - Istituto di Candiolo, Candiolo, Italy |
| authorships[6].institutions[0].id | https://openalex.org/I4210151091 |
| authorships[6].institutions[0].ror | https://ror.org/04wadq306 |
| authorships[6].institutions[0].type | nonprofit |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210151091, https://openalex.org/I4210153126, https://openalex.org/I4210167100 |
| authorships[6].institutions[0].country_code | IT |
| authorships[6].institutions[0].display_name | Candiolo Cancer Institute |
| authorships[6].institutions[1].id | https://openalex.org/I4210153126 |
| authorships[6].institutions[1].ror | https://ror.org/04tfzc498 |
| authorships[6].institutions[1].type | healthcare |
| authorships[6].institutions[1].lineage | https://openalex.org/I4210153126 |
| authorships[6].institutions[1].country_code | IT |
| authorships[6].institutions[1].display_name | Istituti di Ricovero e Cura a Carattere Scientifico |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Massimo Aglietta |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Medical Oncology Department, IRCCS - Istituto di Candiolo, Candiolo, Italy |
| authorships[7].author.id | https://openalex.org/A5070358745 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-7979-4795 |
| authorships[7].author.display_name | Fabio Gelsomino |
| authorships[7].countries | IT |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I122346577 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Oncology and Hematology, Division of Oncology, University Hospital of Modena, Modena, Italy |
| authorships[7].institutions[0].id | https://openalex.org/I122346577 |
| authorships[7].institutions[0].ror | https://ror.org/02d4c4y02 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I122346577 |
| authorships[7].institutions[0].country_code | IT |
| authorships[7].institutions[0].display_name | University of Modena and Reggio Emilia |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Fabio Gelsomino |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Oncology and Hematology, Division of Oncology, University Hospital of Modena, Modena, Italy |
| authorships[8].author.id | https://openalex.org/A5006249276 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-8952-4315 |
| authorships[8].author.display_name | Ray McDermott |
| authorships[8].countries | IE |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210103332, https://openalex.org/I4210115218 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Medical Oncology, St Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland |
| authorships[8].institutions[0].id | https://openalex.org/I4210103332 |
| authorships[8].institutions[0].ror | https://ror.org/01dpkyq75 |
| authorships[8].institutions[0].type | facility |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210103332 |
| authorships[8].institutions[0].country_code | IE |
| authorships[8].institutions[0].display_name | Cancer Trials Ireland |
| authorships[8].institutions[1].id | https://openalex.org/I4210115218 |
| authorships[8].institutions[1].ror | https://ror.org/029tkqm80 |
| authorships[8].institutions[1].type | healthcare |
| authorships[8].institutions[1].lineage | https://openalex.org/I4210115218 |
| authorships[8].institutions[1].country_code | IE |
| authorships[8].institutions[1].display_name | St. Vincent's University Hospital |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Ray McDermott |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Medical Oncology, St Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland |
| authorships[9].author.id | https://openalex.org/A5034884991 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Ka Yeung Mark Wong |
| authorships[9].countries | AU |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I2803024705 |
| authorships[9].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia |
| authorships[9].institutions[0].id | https://openalex.org/I2803024705 |
| authorships[9].institutions[0].ror | https://ror.org/04gp5yv64 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I2803024705 |
| authorships[9].institutions[0].country_code | AU |
| authorships[9].institutions[0].display_name | Westmead Hospital |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Ka Yeung Mark Wong |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia |
| authorships[10].author.id | https://openalex.org/A5074731037 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-5725-4533 |
| authorships[10].author.display_name | Michael A. Morse |
| authorships[10].countries | US |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210126298 |
| authorships[10].affiliations[0].raw_affiliation_string | Department of Medicine, Duke University Medical Center, Durham, NC, USA |
| authorships[10].institutions[0].id | https://openalex.org/I4210126298 |
| authorships[10].institutions[0].ror | https://ror.org/03njmea73 |
| authorships[10].institutions[0].type | healthcare |
| authorships[10].institutions[0].lineage | https://openalex.org/I4210126298, https://openalex.org/I4210144876 |
| authorships[10].institutions[0].country_code | US |
| authorships[10].institutions[0].display_name | Duke Medical Center |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Michael A. Morse |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Department of Medicine, Duke University Medical Center, Durham, NC, USA |
| authorships[11].author.id | https://openalex.org/A5090645179 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-6372-1230 |
| authorships[11].author.display_name | Eric Van Cutsem |
| authorships[11].countries | BE |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I99464096 |
| authorships[11].affiliations[0].raw_affiliation_string | Department of Digestive Oncology, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium |
| authorships[11].institutions[0].id | https://openalex.org/I99464096 |
| authorships[11].institutions[0].ror | https://ror.org/05f950310 |
| authorships[11].institutions[0].type | education |
| authorships[11].institutions[0].lineage | https://openalex.org/I99464096 |
| authorships[11].institutions[0].country_code | BE |
| authorships[11].institutions[0].display_name | KU Leuven |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Eric Van Cutsem |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Department of Digestive Oncology, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium |
| authorships[12].author.id | https://openalex.org/A5060058983 |
| authorships[12].author.orcid | https://orcid.org/0000-0003-2122-1948 |
| authorships[12].author.display_name | Alain Hendlisz |
| authorships[12].countries | BE |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I2801838318 |
| authorships[12].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium |
| authorships[12].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[12].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[12].institutions[0].type | healthcare |
| authorships[12].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[12].institutions[0].country_code | BE |
| authorships[12].institutions[0].display_name | Institut Jules Bordet |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Alain Hendlisz |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium |
| authorships[13].author.id | https://openalex.org/A5010469485 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-0269-9615 |
| authorships[13].author.display_name | Dana B. Cardin |
| authorships[13].countries | US |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I901861585 |
| authorships[13].affiliations[0].raw_affiliation_string | Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA |
| authorships[13].institutions[0].id | https://openalex.org/I901861585 |
| authorships[13].institutions[0].ror | https://ror.org/05dq2gs74 |
| authorships[13].institutions[0].type | healthcare |
| authorships[13].institutions[0].lineage | https://openalex.org/I4210162197, https://openalex.org/I901861585 |
| authorships[13].institutions[0].country_code | US |
| authorships[13].institutions[0].display_name | Vanderbilt University Medical Center |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Dana B. Cardin |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA |
| authorships[14].author.id | https://openalex.org/A5082449165 |
| authorships[14].author.orcid | https://orcid.org/0000-0003-0658-5903 |
| authorships[14].author.display_name | Bart Neyns |
| authorships[14].countries | BE |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I4210126764 |
| authorships[14].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium |
| authorships[14].institutions[0].id | https://openalex.org/I4210126764 |
| authorships[14].institutions[0].ror | https://ror.org/038f7y939 |
| authorships[14].institutions[0].type | healthcare |
| authorships[14].institutions[0].lineage | https://openalex.org/I4210126764 |
| authorships[14].institutions[0].country_code | BE |
| authorships[14].institutions[0].display_name | Universitair Ziekenhuis Brussel |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Bart Neyns |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium |
| authorships[15].author.id | https://openalex.org/A5061348179 |
| authorships[15].author.orcid | https://orcid.org/0000-0001-8672-6379 |
| authorships[15].author.display_name | Andrew Hill |
| authorships[15].countries | AU |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I4210119934 |
| authorships[15].affiliations[0].raw_affiliation_string | Tasman Oncology Research Ltd., Southport, Qld, Australia |
| authorships[15].institutions[0].id | https://openalex.org/I4210119934 |
| authorships[15].institutions[0].ror | https://ror.org/02cyrpr98 |
| authorships[15].institutions[0].type | other |
| authorships[15].institutions[0].lineage | https://openalex.org/I4210119934 |
| authorships[15].institutions[0].country_code | AU |
| authorships[15].institutions[0].display_name | Trans Tasman Radiation Oncology Group |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Andrew Hill |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Tasman Oncology Research Ltd., Southport, Qld, Australia |
| authorships[16].author.id | https://openalex.org/A5060102963 |
| authorships[16].author.orcid | |
| authorships[16].author.display_name | Anuradha Krishnamurthy |
| authorships[16].countries | US |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I4210128526 |
| authorships[16].affiliations[0].raw_affiliation_string | Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA |
| authorships[16].institutions[0].id | https://openalex.org/I4210128526 |
| authorships[16].institutions[0].ror | https://ror.org/03bw34a45 |
| authorships[16].institutions[0].type | facility |
| authorships[16].institutions[0].lineage | https://openalex.org/I170201317, https://openalex.org/I4210128526 |
| authorships[16].institutions[0].country_code | US |
| authorships[16].institutions[0].display_name | UPMC Hillman Cancer Center |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Anuradha Krishnamurthy |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA |
| authorships[17].author.id | https://openalex.org/A5081403428 |
| authorships[17].author.orcid | |
| authorships[17].author.display_name | Franklin Chen |
| authorships[17].countries | US |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I2802152183 |
| authorships[17].affiliations[0].raw_affiliation_string | Department of Cellular Therapy and Developmental Therapeutics, Novant Health Cancer Institute, Winston-Salem, NC, USA |
| authorships[17].institutions[0].id | https://openalex.org/I2802152183 |
| authorships[17].institutions[0].ror | https://ror.org/04nv2wh79 |
| authorships[17].institutions[0].type | healthcare |
| authorships[17].institutions[0].lineage | https://openalex.org/I2802152183 |
| authorships[17].institutions[0].country_code | US |
| authorships[17].institutions[0].display_name | Novant Health |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Franklin Chen |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | Department of Cellular Therapy and Developmental Therapeutics, Novant Health Cancer Institute, Winston-Salem, NC, USA |
| authorships[18].author.id | https://openalex.org/A5043633072 |
| authorships[18].author.orcid | https://orcid.org/0009-0003-2189-7304 |
| authorships[18].author.display_name | Samith T. Kochuparambil |
| authorships[18].countries | US |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I4210165573 |
| authorships[18].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Minnesota Oncology, Minneapolis, MN, USA |
| authorships[18].institutions[0].id | https://openalex.org/I4210165573 |
| authorships[18].institutions[0].ror | https://ror.org/05vmsw483 |
| authorships[18].institutions[0].type | healthcare |
| authorships[18].institutions[0].lineage | https://openalex.org/I4210165573 |
| authorships[18].institutions[0].country_code | US |
| authorships[18].institutions[0].display_name | Minnesota Oncology |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Samith Kochuparambil |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | Department of Medical Oncology, Minnesota Oncology, Minneapolis, MN, USA |
| authorships[19].author.id | https://openalex.org/A5025089795 |
| authorships[19].author.orcid | https://orcid.org/0000-0002-5434-439X |
| authorships[19].author.display_name | Robert R. Jenq |
| authorships[19].countries | US |
| authorships[19].affiliations[0].institution_ids | https://openalex.org/I1343551460 |
| authorships[19].affiliations[0].raw_affiliation_string | Department of Genomic Medicine and Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA |
| authorships[19].institutions[0].id | https://openalex.org/I1343551460 |
| authorships[19].institutions[0].ror | https://ror.org/04twxam07 |
| authorships[19].institutions[0].type | healthcare |
| authorships[19].institutions[0].lineage | https://openalex.org/I1343551460 |
| authorships[19].institutions[0].country_code | US |
| authorships[19].institutions[0].display_name | The University of Texas MD Anderson Cancer Center |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | Robert R. Jenq |
| authorships[19].is_corresponding | False |
| authorships[19].raw_affiliation_strings | Department of Genomic Medicine and Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA |
| authorships[20].author.id | https://openalex.org/A5110920554 |
| authorships[20].author.orcid | |
| authorships[20].author.display_name | Sandzhar Abdullaev |
| authorships[20].countries | US |
| authorships[20].affiliations[0].institution_ids | https://openalex.org/I4210091812 |
| authorships[20].affiliations[0].raw_affiliation_string | Department of Clinical Development, Bristol Myers Squibb, Princeton, NJ, USA |
| authorships[20].institutions[0].id | https://openalex.org/I4210091812 |
| authorships[20].institutions[0].ror | https://ror.org/00gtmwv55 |
| authorships[20].institutions[0].type | company |
| authorships[20].institutions[0].lineage | https://openalex.org/I4210091812 |
| authorships[20].institutions[0].country_code | US |
| authorships[20].institutions[0].display_name | Bristol-Myers Squibb (United States) |
| authorships[20].author_position | middle |
| authorships[20].raw_author_name | Sandzhar Abdullaev |
| authorships[20].is_corresponding | False |
| authorships[20].raw_affiliation_strings | Department of Clinical Development, Bristol Myers Squibb, Princeton, NJ, USA |
| authorships[21].author.id | https://openalex.org/A5045005795 |
| authorships[21].author.orcid | https://orcid.org/0000-0002-4115-0115 |
| authorships[21].author.display_name | Beilei He |
| authorships[21].countries | US |
| authorships[21].affiliations[0].institution_ids | https://openalex.org/I4210091812 |
| authorships[21].affiliations[0].raw_affiliation_string | Department of Global Biostatistics and Data Science, Bristol Myers Squibb, Princeton, NJ, USA |
| authorships[21].institutions[0].id | https://openalex.org/I4210091812 |
| authorships[21].institutions[0].ror | https://ror.org/00gtmwv55 |
| authorships[21].institutions[0].type | company |
| authorships[21].institutions[0].lineage | https://openalex.org/I4210091812 |
| authorships[21].institutions[0].country_code | US |
| authorships[21].institutions[0].display_name | Bristol-Myers Squibb (United States) |
| authorships[21].author_position | middle |
| authorships[21].raw_author_name | Beilei He |
| authorships[21].is_corresponding | False |
| authorships[21].raw_affiliation_strings | Department of Global Biostatistics and Data Science, Bristol Myers Squibb, Princeton, NJ, USA |
| authorships[22].author.id | https://openalex.org/A5022346083 |
| authorships[22].author.orcid | |
| authorships[22].author.display_name | Ruslan D. Novosiadly |
| authorships[22].countries | US |
| authorships[22].affiliations[0].institution_ids | https://openalex.org/I4210091812 |
| authorships[22].affiliations[0].raw_affiliation_string | Department of Translational Medicine, Bristol Myers Squibb, Princeton, NJ, USA |
| authorships[22].institutions[0].id | https://openalex.org/I4210091812 |
| authorships[22].institutions[0].ror | https://ror.org/00gtmwv55 |
| authorships[22].institutions[0].type | company |
| authorships[22].institutions[0].lineage | https://openalex.org/I4210091812 |
| authorships[22].institutions[0].country_code | US |
| authorships[22].institutions[0].display_name | Bristol-Myers Squibb (United States) |
| authorships[22].author_position | middle |
| authorships[22].raw_author_name | Ruslan Novosiadly |
| authorships[22].is_corresponding | False |
| authorships[22].raw_affiliation_strings | Department of Translational Medicine, Bristol Myers Squibb, Princeton, NJ, USA |
| authorships[23].author.id | https://openalex.org/A5006348751 |
| authorships[23].author.orcid | https://orcid.org/0000-0001-9647-3416 |
| authorships[23].author.display_name | Scott Kopetz |
| authorships[23].countries | US |
| authorships[23].affiliations[0].institution_ids | https://openalex.org/I1343551460 |
| authorships[23].affiliations[0].raw_affiliation_string | Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA |
| authorships[23].institutions[0].id | https://openalex.org/I1343551460 |
| authorships[23].institutions[0].ror | https://ror.org/04twxam07 |
| authorships[23].institutions[0].type | healthcare |
| authorships[23].institutions[0].lineage | https://openalex.org/I1343551460 |
| authorships[23].institutions[0].country_code | US |
| authorships[23].institutions[0].display_name | The University of Texas MD Anderson Cancer Center |
| authorships[23].author_position | last |
| authorships[23].raw_author_name | Scott Kopetz |
| authorships[23].is_corresponding | False |
| authorships[23].raw_affiliation_strings | Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.nature.com/articles/s41467-025-63960-8.pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10158 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | Cancer Immunotherapy and Biomarkers |
| cited_by_count | 0 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1038/s41467-025-63960-8 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S64187185 |
| best_oa_location.source.issn | 2041-1723 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2041-1723 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Nature Communications |
| best_oa_location.source.host_organization | https://openalex.org/P4310319908 |
| best_oa_location.source.host_organization_name | Nature Portfolio |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310319908 |
| best_oa_location.license | cc-by-nc-nd |
| best_oa_location.pdf_url | https://www.nature.com/articles/s41467-025-63960-8.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Nature Communications |
| best_oa_location.landing_page_url | https://doi.org/10.1038/s41467-025-63960-8 |
| primary_location.id | doi:10.1038/s41467-025-63960-8 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S64187185 |
| primary_location.source.issn | 2041-1723 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2041-1723 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Nature Communications |
| primary_location.source.host_organization | https://openalex.org/P4310319908 |
| primary_location.source.host_organization_name | Nature Portfolio |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310319908 |
| primary_location.license | cc-by-nc-nd |
| primary_location.pdf_url | https://www.nature.com/articles/s41467-025-63960-8.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Nature Communications |
| primary_location.landing_page_url | https://doi.org/10.1038/s41467-025-63960-8 |
| publication_date | 2025-10-06 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W4318575241, https://openalex.org/W2890308496, https://openalex.org/W2159064822, https://openalex.org/W4283512735, https://openalex.org/W3110528877, https://openalex.org/W2983284890, https://openalex.org/W3206775306, https://openalex.org/W2784868445, https://openalex.org/W2739132742, https://openalex.org/W4286295302, https://openalex.org/W4307401860, https://openalex.org/W4384120435, https://openalex.org/W4378978220, https://openalex.org/W1984642649, https://openalex.org/W2339723519, https://openalex.org/W2942698526, https://openalex.org/W2943688939, https://openalex.org/W2635951006, https://openalex.org/W2897815318, https://openalex.org/W2904444972, https://openalex.org/W2954094199, https://openalex.org/W2987116731, https://openalex.org/W3149557634, https://openalex.org/W3187890850, https://openalex.org/W2914335731, https://openalex.org/W1994993231, https://openalex.org/W2055901890, https://openalex.org/W4391096773, https://openalex.org/W4404784379, https://openalex.org/W4406818361, https://openalex.org/W2955199260, https://openalex.org/W2146290346, https://openalex.org/W2117564738, https://openalex.org/W2980339751, https://openalex.org/W2169456326, https://openalex.org/W2532808087, https://openalex.org/W2114104545, https://openalex.org/W2406250479, https://openalex.org/W3128646645, https://openalex.org/W4226440498 |
| referenced_works_count | 40 |
| abstract_inverted_index.2 | 25 |
| abstract_inverted_index.In | 79 |
| abstract_inverted_index.be | 130 |
| abstract_inverted_index.by | 112 |
| abstract_inverted_index.in | 3, 11, 22, 55, 140 |
| abstract_inverted_index.is | 65, 110, 144 |
| abstract_inverted_index.of | 47, 60, 90, 116, 137 |
| abstract_inverted_index.we | 30 |
| abstract_inverted_index.142 | 27, 37 |
| abstract_inverted_index.and | 2, 44, 50, 73, 88, 101 |
| abstract_inverted_index.are | 93 |
| abstract_inverted_index.for | 132 |
| abstract_inverted_index.per | 70, 98 |
| abstract_inverted_index.the | 23, 45, 113, 133 |
| abstract_inverted_index.from | 35 |
| abstract_inverted_index.gene | 62 |
| abstract_inverted_index.plus | 52, 106 |
| abstract_inverted_index.than | 125 |
| abstract_inverted_index.that | 121 |
| abstract_inverted_index.they | 119 |
| abstract_inverted_index.with | 5, 13, 67, 76, 95, 104 |
| abstract_inverted_index.Here, | 29 |
| abstract_inverted_index.While | 108 |
| abstract_inverted_index.alone | 1 |
| abstract_inverted_index.indel | 86 |
| abstract_inverted_index.might | 129 |
| abstract_inverted_index.phase | 24 |
| abstract_inverted_index.these | 56, 117, 138 |
| abstract_inverted_index.tumor | 82, 85, 122, 127 |
| abstract_inverted_index.Higher | 58 |
| abstract_inverted_index.cancer | 21 |
| abstract_inverted_index.higher | 81 |
| abstract_inverted_index.nature | 115 |
| abstract_inverted_index.rather | 124 |
| abstract_inverted_index.report | 31 |
| abstract_inverted_index.study. | 28 |
| abstract_inverted_index.tissue | 42 |
| abstract_inverted_index.benefit | 10, 75, 103 |
| abstract_inverted_index.between | 40 |
| abstract_inverted_index.burden, | 84, 87 |
| abstract_inverted_index.degrees | 89 |
| abstract_inverted_index.durable | 8 |
| abstract_inverted_index.larger, | 141 |
| abstract_inverted_index.limited | 111 |
| abstract_inverted_index.studies | 143 |
| abstract_inverted_index.suggest | 120 |
| abstract_inverted_index.treated | 15 |
| abstract_inverted_index.various | 41 |
| abstract_inverted_index.analyses | 34 |
| abstract_inverted_index.baseline | 126 |
| abstract_inverted_index.clinical | 9 |
| abstract_inverted_index.efficacy | 46 |
| abstract_inverted_index.findings | 139 |
| abstract_inverted_index.improved | 68, 96 |
| abstract_inverted_index.patients | 12 |
| abstract_inverted_index.response | 69, 97 |
| abstract_inverted_index.survival | 74, 102 |
| abstract_inverted_index.CheckMate | 26, 36 |
| abstract_inverted_index.Nivolumab | 0 |
| abstract_inverted_index.analyses, | 118 |
| abstract_inverted_index.biomarker | 33 |
| abstract_inverted_index.contrast, | 80 |
| abstract_inverted_index.efficacy. | 135 |
| abstract_inverted_index.important | 131 |
| abstract_inverted_index.nivolumab | 48, 51, 77, 105 |
| abstract_inverted_index.patients. | 57 |
| abstract_inverted_index.Validation | 136 |
| abstract_inverted_index.assessment | 72, 100 |
| abstract_inverted_index.associated | 66, 94 |
| abstract_inverted_index.biomarkers | 43 |
| abstract_inverted_index.colorectal | 20 |
| abstract_inverted_index.evaluating | 38 |
| abstract_inverted_index.expression | 59, 63 |
| abstract_inverted_index.ipilimumab | 6, 53 |
| abstract_inverted_index.metastatic | 19 |
| abstract_inverted_index.mutational | 83 |
| abstract_inverted_index.necessary. | 145 |
| abstract_inverted_index.previously | 14 |
| abstract_inverted_index.randomized | 142 |
| abstract_inverted_index.signatures | 64 |
| abstract_inverted_index.combination | 4, 54 |
| abstract_inverted_index.exploratory | 32, 114 |
| abstract_inverted_index.instability | 92 |
| abstract_inverted_index.ipilimumab. | 107 |
| abstract_inverted_index.monotherapy | 49 |
| abstract_inverted_index.antigenicity | 123 |
| abstract_inverted_index.associations | 39 |
| abstract_inverted_index.demonstrated | 7 |
| abstract_inverted_index.inflammation | 128 |
| abstract_inverted_index.investigator | 71, 99 |
| abstract_inverted_index.monotherapy. | 78 |
| abstract_inverted_index.combinatorial | 134 |
| abstract_inverted_index.interpretation | 109 |
| abstract_inverted_index.microsatellite | 16, 91 |
| abstract_inverted_index.repair-deficient | 18 |
| abstract_inverted_index.inflammation-related | 61 |
| abstract_inverted_index.instability-high/mismatch | 17 |
| cited_by_percentile_year | |
| countries_distinct_count | 6 |
| institutions_distinct_count | 24 |
| citation_normalized_percentile.value | 0.61448051 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |